Dermatitis News

Tradipitant was considered safe and effective as monotherapy for chronic pruritus in patients with atopic dermatitis despite a high placebo effect, according to a drugmaker’s press release.

An FDA advisory committee agreed there is an unmet medical need for systemic products, drugs, and biologics, along with additional clinical studies, for the treatment of children with atopic dermatitis who do not respond adequately to topical therapy.

Adults in the United States with eczema experience higher out-of-pocket health costs and increased lost work days and health care utilization with limited access to care compared with the general population, according to recently published study results.

Cipher Pharmaceuticals announced it has acquired three products from Astion Pharma that are focused on inflammatory dermatological diseases.

 Researchers presented results from an evaluation of characteristics and demographics of adolescents with chronic idiopathic urticaria and chronic spontaneous urticaria in placebo-controlled omalizumab trials at the American Academy of Allergy, Asthma and Immunology Annual Meeting in Houston.

HOUSTON — Dupilumab reduced patient-reported itch when compared with placebo in adults with moderate-to-severe atopic dermatitis, according to data presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting.

Longer duration of breastfeeding weakened the association between filaggrin gene variants and eczema development in early years of life, according to research presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting in Houston.

HOUSTON — Immediate treatment effectively reduced disease-related morbidity of C1 Inhibitor Deficiency in patients with hereditary angioedema, according to data presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting.

Early, aggressive treatment of patients with infantile atopic dermatitis significantly reduced food allergy incidence by 18 months of age, according to research presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting in Houston.

Patients with chronic idiopathic urticaria or chronic spontaneous urticaria had an increased risk of oral corticosteroid-related adverse events with an increase in cumulative exposure to the drugs, according to research presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting.